Body Weight and Bone Density Changes in Patients with Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor-alpha Treatment.
- Author:
Jangwon LEE
1
;
Minsuk JUNG
;
Donghyun KIM
;
Seunghyun LEE
;
Sook Kyung OH
;
Youngsun JO
;
Sanghwan BYUN
;
Kyoungmin NAM
;
Choongwon LEE
Author Information
1. Department of Internal Medicine, Wallace Memorial Baptist Hospital, Busan, Korea. resdy@naver.com
- Publication Type:Original Article
- Keywords:
Spondylitis;
Ankylosing;
Anti-tumor necrosis factor-alpha;
Cachexia;
Bone mineral density;
Body weight
- MeSH:
Antibodies, Monoclonal, Humanized;
Baths;
Blood Sedimentation;
Body Weight*;
Bone Density*;
C-Reactive Protein;
Cachexia;
Femur;
Humans;
Male;
Necrosis*;
Retrospective Studies;
Spine;
Spondylitis;
Spondylitis, Ankylosing*;
Adalimumab
- From:Korean Journal of Medicine
2013;85(5):489-494
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: To determine the changes in body weight and bone mineral density in patients with ankylosing spondylitis (AS) receiving anti-tumor necrosis factor-alpha (TNF-alpha) treatment. METHODS: Thirty-one patients with AS (25 males and 6 females) who fulfilled the Modified New York Criteria for AS were included in this retrospective study. All patients had active disease that eventually required anti-TNF-alpha treatment. Each patient received anti-TNF-alpha treatment (etanercept 25 mg twice weekly or adalimumab 40 mg twice monthly) for more than 2 years. Body weight, disease activity as Bath ankylosing spondylitis disease activity index (BASDAI), C-reactive protein, erythrocyte sedimentation rate (ESR), lumbar bone mineral density (LBMD), and femoral bone mineral density (FBMD) were measured at baseline and at 1 and 2 years after initiating anti-TNF-alpha treatment. RESULTS: There was a significant increase in mean body weight at 1 year (1.1 +/- 3.8 kg) and at 2 years (1.7 +/- 4.8 kg) compared with baseline. The gains in mean BMD of the lumbar spine were significant at 1 year (0.4 +/- 0.4) and 2 years (0.5 +/- 0.7) compared with baseline. Mean BMD of the femur was also increased at 1 year (0.08 +/- 0.7) and 2 years (0.1 +/- 0.8) compared with baseline, but these differences were not statistically significant. There were significant decreases in BASDAI at 1 year (-3.3 +/- 2.8) and at 2 years (-3.6 +/- 2.8) compared with baseline. CONCLUSIONS: This study showed significant increases in body weight, lumbar BMD, and BASDAI at 1 year and 2 years in patients with ankylosing spondylitis after receiving anti-TNF-alpha treatment.
